PeppiLibrary

Healing

BPC-157 peptide reference

Body protection compound. Researched for soft-tissue and gut-lining recovery.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing BPC-157 notes
Default dose label250 mcg
Preferred routeSubQ
Frequency label1–2× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Extensive animal studies; limited human data

Research chemical (US/EU)

Route map

How records are usually labeled

1 SubQ
2 IM
3 Oral

Inject as close to the area being treated as practical for localised issues; rotate sites for systemic dosing.

Vial timeline

Storage cues to log

Before mixSealed lyophilized powder: refrigerate 2–8 °C; can freeze for long-term storage.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 250 mcg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for BPC-157. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is most studied for tendon, ligament and soft-tissue recovery, gut barrier protection, and modulation of inflammation. Often combined with TB-500 in healing-focused protocols.

Also known as: PL 14736, Body Protection Compound 157, Pentadecapeptide BPC-157.

Tendon and ligament recoveryJoint pain and inflammationGut barrier integrity (IBS, GERD, ulcers)Wound healing

Mechanism and timing snapshot

Promotes angiogenesis through the VEGFR2/FAK/paxillin pathway, modulates the nitric oxide system, upregulates growth-hormone-receptor expression, and stabilises the gut–brain axis.

Onset label15 min
Catalog onset field, when available.
Half-life label4 hr
subQ ~4h, oral ~30min before first-pass degradation
Duration label8 hr
Catalog duration field, when available.
subQ High
oral Low (~1–2%) but locally active in the GI tract
topical Limited

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose250 mcg
Catalog dose range200 mcg - 1 mg
Default routeSubQ
Frequency label1–2× daily
Best time labelAnytime — split AM/PM if dosing twice daily.
Food noteNone. Can be taken with or without food.

Catalog protocol note

250 mcg subQ 1–2× daily for 4–6 weeks, then re-evaluate.

Routes and site notes

Available route labelsSubQ, IM, Oral
Preferred route labelSubQ
Common site labelsAbdomen, Near injury site, Deltoid
Site rotation noteInject as close to the area being treated as practical for localised issues; rotate sites for systemic dosing.

Chemistry

SequenceGEPPPGKPADDAGLV
Amino acids15
Molecular formulaC62H98N16O22
Molecular weight1419.5 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note5 mg in 2 mL → 0.10 mL = 250 mcg (10 units on a 100-unit insulin syringe).
Before reconstitutionSealed lyophilized powder: refrigerate 2–8 °C; can freeze for long-term storage.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Mild flushing at injection site
  • Occasional fatigue in first week
  • Nausea
  • Headache

Contraindications and warnings

  • Active malignancy (theoretical concern from angiogenic activity — discuss with a clinician)
  • Not approved for human use by the FDA — sold as research-only.

Other considerations

  • Effects build over weeks; not an acute analgesic.
  • Often well-tolerated, but injection-site reactions can occur with repeated dosing in one spot.

Evidence and regulatory context

Evidence levelExtensive animal studies; limited human data
FDA approvedNo
Regulatory statusResearch chemical (US/EU)
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withtb-500
Avoid combining noteNot listed
Typical cycle label4–6
Typical break label2–4
Cycle guidanceMost users run 4–6 week cycles with 2–4 week breaks. Some run continuously for chronic injuries; data on long-term continuous use is limited.

Tracking tips

  • For localised issues, inject as close to the affected area as practical.
  • Often combined with TB-500 in recovery stacks — synergy reported anecdotally.
  • Effects build over weeks — don't expect day-one results.

References

Track it in Peppi

Keep BPC-157 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for BPC-157?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use BPC-157?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export BPC-157 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026